Cushing's syndrome (CS) is the classic presentation of endogenous hypercortisolism, with an annual incidence of approximately 2.1 per 100,000 population in China. Patients exhibit a characteristic metabolic disorder termed “four highs and one low”: central obesity (92.3%, waist-to-hip ratio > 0.9), refractory hypertension (87.6%, requiring ≥3 antihypertensive agents), hyperglycemia (78.4%), hypercoagulability (D-dimer > 1.5 μg/mL), plus marked muscle weakness (grip strength reduced by over 30%). The average interval from symptom onset to confirmed diagnosis is 2.1 years, raising the risk of irreversible cardiovascular damage by 4.3-fold. 

I. Characteristic Bodily Morphological Changes in Cushing's Syndrome

Abnormal Fat Distribution

Buffalo hump: Retro-cervical fat pad thickness > 3 cm (measured by ultrasound)

Supraclavicular fat pads: Fat nodules > 2 cm in diameter (91.4% positive on palpation)

Central obesity: Waist circumference increases by > 10 cm annually (normal < 2 cm) Mechanism: Cortisol induces overexpression of PPARγ in visceral adipose tissue.

Cutaneous Pathological Lesions

Purplish Striae Features

Width > 1 cm, predominantly distributed over the lower abdomen and medial thighs

Dark purplish-red hue (distinguished from silvery-white striae of pregnancy)

Pathogenesis: Rupture of dermal elastic fibers coupled with capillary dilatation

Thin Fragile Skin

Venous plexus visible on the dorsum of hands; skin thickness < 0.8 mm.

II. Metabolic Complications of Cushing's Syndrome

Mechanisms of Refractory Hypertension

• Mineralocorticoid-like effect: Inhibition of renal tubular 11β-HSD2 enzyme

• Enhanced vascular reactivity: Vasoconstrictive response to norepinephrine increased 3-fold

• Clinical data: 84.7% of patients require combined spironolactone and ACEI therapy for blood pressure control

Triad of Disrupted Glucose Metabolism

• Fasting blood glucose > 7.0 mmol/L, unresponsive to dietary intervention

• Homeostatic model assessment-insulin resistance index (HOMA-IR) > 5.0

• Ketosis tendency: β-hydroxybutyrate > 1.0 mmol/L Insulin demand for CS-induced diabetes is 2.1 times higher than that for type 2 diabetes mellitus.

III. Catabolic Effects on Protein Metabolism

Features of Muscle Wasting

• Proximal myopathy: Requires upper limb support to rise from squatting (quadriceps muscle strength grade 3)

Electromyographic alterations: Motor unit potential amplitude reduced by > 40%

• Serum biomarker: Creatine kinase MM isoenzyme (CK-MM) > 200 U/L

Fragile Skin Syndrome

• Spontaneous ecchymoses: Bruises > 3 cm without trauma

• Delayed wound healing: Minor epidermal abrasions take >14 days to heal (normal: 3–5 days) Pathogenesis: Dermal collagen synthesis reduced by 65%.

IV. Endocrine Axis Dysregulation

Suppressed Gonadal Function

Female Patients

• Oligomenorrhea (cycle interval > 45 days): 93.2% prevalence

• Hirsutism: Ferriman-Gallwey score > 8

Male Patients

• Erectile dysfunction: International Index of Erectile Function (IIEF-5) score < 10

• Testicular atrophy: Testicular volume < 12 mL

Skeletal Metabolic Crisis

• Vertebral compression fractures: 58.7% among patients with T-score < −3.0

• Bone turnover marker: Serum C-telopeptide of type I collagen (CTX) > 1.0 ng/mL (normal < 0.5 ng/mL)

• Pain pattern: Nocturnal back pain exacerbation (VAS score > 6)

V. Neuropsychiatric Manifestations

Triad of Mood Disorders

• Labile mood: Alternating euphoria and depression within 24 hours

• Cognitive decline: Mini-Mental State Examination (MMSE) score drops by >4 points per year

• Sleep disturbance: Sleep onset latency > 60 minutes MRI evidence: Hippocampal volume atrophy rate >3% annually (normal < 0.5%)

Pseudotumor Cerebri Manifestations

• Papilledema: Frisen grade ≥ II

• Visual field defects: Physiological blind spot enlarged by >5° Mechanism: Increased cerebrospinal fluid production plus impaired arachnoid granulation absorption.

VI. Etiological Differential Diagnosis

Differentiation of ACTH-Dependent Cushing's Syndrome

Biomarkers of Adrenal-Derived Cushing's Syndrome

• Loss of diurnal cortisol rhythm: Midnight cortisol > 5 μg/dL

• Normal or reduced DHEA-S levels (distinguished from elevated levels in ACTH-dependent subtypes)

• Adrenal CT identifies unilateral adenoma (diameter > 2 cm)

Frequently Asked Questions on Cushing's Syndrome

Q1: What is the core constellation of symptoms for Cushing's Syndrome?

Four diagnostic gold-standard manifestations (3 out of 4 positive warrants midnight salivary cortisol screening):

• Central obesity: Annual waist circumference gain > 8 cm with thin extremities

•Cutaneous lesions: Wide purplish striae (>1 cm) + thin fragile skin

• Metabolic disturbance: Refractory hypertension + rapidly progressive diabetes

• Muscle wasting: Reliance on upper limbs to stand from squatting position

Q2: How is this differentiated from simple obesity?

Three fundamental distinctions:

• Fat distribution: CS causes exclusive visceral fat deposition (CT shows VAT > 150 cm²)

• Basal metabolism: Basal metabolic rate reduced by >25% in CS (normal in simple obesity)

• Comorbidity spectrum: CS is accompanied by rapid bone loss (bone mineral density declines >3% yearly) and sarcopenia (muscle mass preserved in ordinary obesity)

Screening recommendation: Perform 24-hour urinary free cortisol testing for patients with waist-to-hip ratio > 0.9 concurrent with purplish striae.